Medication-based Comorbidity Measures and Prostate Cancer Treatment Selection

Area of Science:

• Urology
• Oncology
• Health Services Research

Background:

• Comorbidities significantly impact patient health and treatment decisions.
• Understanding the influence of comorbidities on prostate cancer management is crucial for personalized care.

Purpose of the Study:

• To investigate the association between comorbidities and the selection of primary treatment for prostate cancer.
• To determine how specific comorbid conditions affect treatment choices in prostate cancer patients.

Main Methods:

• A study of 12,603 South Australian men diagnosed with prostate cancer (2003-2019).
• Comorbidity assessed using a medication-based index (Rx-Risk) one year prior to diagnosis.
• Binomial logistic regression analyses adjusted for sociodemographic and tumor characteristics.

Main Results:

• Higher comorbidity scores (Rx-Risk ≥3) were associated with reduced likelihood of radical prostatectomy (RP) and increased likelihood of androgen deprivation therapy (ADT) alone, external beam radiotherapy (EBRT), or watchful waiting (WW).
• Specific conditions like cardiac disorders, diabetes, thrombosis, and depression influenced treatment selection, often favoring non-surgical options.
• Age demonstrated a greater impact on treatment choice than comorbidity levels.

Conclusions:

• Elevated comorbidity burden is linked to less frequent RP and more frequent use of EBRT, WW, and ADT alone in prostate cancer management.
• Individual comorbid conditions play a significant role in shaping primary treatment decisions for prostate cancer.